Galectin-1 Therapeutic Application for Muscular Dystrophy and Autoimmune Diseases ID: 2019-015

This invention leverages the therapeutic potential of Galectin-1 to treat muscular dystrophy and autoimmune diseases effectively.

Technology Overview

The document details an innovative approach focusing on the therapeutic application of Galectin-1, a protein known for modulating immune responses and promoting myogenic improvements, particularly in the context of limb-girdle muscular dystrophy type 2B (LGMD2B). It outlines the discovery of Galectin-1's biologically active form and the specific protein domain essential for its therapeutic effects, alongside the development of a synthetic recombinant variant designed for enhanced therapeutic efficacy.

Key Advantages

• Unveils the biologically active form of Galectin-1, enhancing therapeutic precision
• Identifies crucial protein domains for therapeutic effectiveness, advancing understanding and application
• Development of a synthetic recombinant variant of Galectin-1 with improved therapeutic profile
• Shows notable improvements in muscle function in vivo, specifically for LGMD2B

Problems Addressed

• Addresses the lack of clarity on the therapeutic mechanisms of Galectin-1 in prior studies
• Provides a targeted approach to treating muscular dystrophy and certain autoimmune diseases
• Reduces inflammation and repairs muscle membrane damage effectively

Market Applications

• Pharmaceutical treatments for limb-girdle muscular dystrophy and other related muscular disorders
• Autoimmune disease management through immune response modulation
• Potential for development into drugs with enhanced efficacy and specificity for muscular and autoimmune conditions

Additional Information

Technology ID: 2019-015
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025